Loading…
Loading…
EQUITY / NASDAQ · XNCM
Coya Therapeutics, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗4.89 USD · -2.3952%
Observed: Oct 1, 2026, 3:20 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 5.01 USD · Volume 101,365
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 43,181,002 USD | — | — |
| Net income | -6,638,260 USD | -6,094,977 USD | — |
| Operating profit | -7,046,988 USD | -6,414,518 USD | — |
| Revenue | 243,745 USD | 163,616 USD | +48.97% |
| Total assets | 47,308,078 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 43,181,002 USD | — | — | 46,822,786 USD | 46,822,786 USD | 28,129,866 USD | — | — |
| Net incomeIncome statement | -6,638,260 USD | -13,845,250 USD | -7,206,990 USD | — | -21,226,107 USD | -2,115,831 USD | -15,517,565 USD | -6,094,977 USD |
| Operating profitIncome statement | -7,046,988 USD | -14,687,205 USD | — | — | -22,555,225 USD | -2,432,897 USD | -16,524,337 USD | -6,414,518 USD |
| RevenueIncome statement | 243,745 USD | 494,892 USD | — | — | 7,945,753 USD | 3,564,254 USD | 3,985,754 USD | 163,616 USD |
| Total assetsBalance sheet | 47,308,078 USD | — | — | 49,950,245 USD | 49,950,245 USD | 32,042,878 USD | — | — |
| Total equityBalance sheet | 43,276,011 USD | — | 48,970,360 USD | 43,028,230 USD | 43,028,230 USD | 27,284,491 USD | — | 28,310,293 USD |
| Total liabilitiesBalance sheet | 4,032,067 USD | — | — | 6,922,015 USD | 6,922,015 USD | 4,758,387 USD | — | — |
| Financing cash flowCash flow statement | — | 10,829,318 USD | — | — | 20,386,927 USD | — | 38,274 USD | — |
| Investing cash flowCash flow statement | — | -886,656 USD | — | — | -1,164,602 USD | — | -515,996 USD | — |
| Operating cash flowCash flow statement | — | -13,584,446 USD | — | — | -10,739,301 USD | — | -9,732,174 USD | — |
| Report source | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 03/16/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/11/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.